CTT Pharma Signs Contract for $3 Million Equity Line of Credit

(TheNewswire)

Tampa, Florida, United States – TheNewswire – September 10, 2025 – CTT Pharmaceuticals Holdings, Inc.(OTCQB:CTTH) is pleased to announce it has signed a contract for a $3Million Equity Line of Credit. The funds from this line will be usedfor the manufacturing of CTT's patented technology. CTT willimmediately move forward with a S-1 filing and will become a SECreporting company. CTT will notify shareholders in greater detail oncethe Equity Line becomes available.

CTT Pharma has not been notified of an approval or denial from the NIHfor clinical trials with Johns Hopkins University. CTT will notifyshareholders once this information becomes available.

Additional Corporate Updates for CTTPharma:

• CTT’s submission to the National Science Foundation (NSF) GrantProgram remains under review, with a funding decision anticipatedtowards the end of the fourth quarter.

• The Small Business Association(SBA) is expected to notify CTTregarding potential approval for a loan, which if awarded, will bedirected towards manufacturing.

• Our scientists are finalizing a manuscript for submission to apeer-reviewed journal. We look forward to sharing the publication oncepeer review is complete and the manuscript has been accepted.

• The PCAOB audit firm that CTT hired successfully completed an auditfor 2024. CTT now has 3 years of PCAOB audits completed.

CTT Pharma – 813-606-0060

Copyright (c) 2025 TheNewswire - All rights reserved.